Discover open access scientific publications

Search, annotate, share and cite publications

Publications by PierGiorgio Di Tullio

Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations

Oncologist

English

Related publications

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Experimental and Therapeutic Medicine

English

P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

Journal of Thoracic Oncology

English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

English

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients

Journal of Thoracic Oncology

English

Metabolic Complete Response With Vinflunine as Second-Line Therapy in a Kidney-Transplanted Patient With Advanced Urothelial Carcinoma: A Case Report

English

Activation of the BMP-BMPR Pathway Conferred Resistance to EGFR-TKIs in Lung Squamous Cell Carcinoma Patients With EGFR Mutations

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2015

English

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma

Clinical Genitourinary Cancer

Oncology

Urology

2016

English

P3.13-08 Assessment of EGFR Gene Mutations in Cf-Dna in Monitoring of Response to EGFR TKIs in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by PierGiorgio Di Tullio

Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations

Related publications

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients

Metabolic Complete Response With Vinflunine as Second-Line Therapy in a Kidney-Transplanted Patient With Advanced Urothelial Carcinoma: A Case Report

Activation of the BMP-BMPR Pathway Conferred Resistance to EGFR-TKIs in Lung Squamous Cell Carcinoma Patients With EGFR Mutations

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma

P3.13-08 Assessment of EGFR Gene Mutations in Cf-Dna in Monitoring of Response to EGFR TKIs in Patients With Lung Adenocarcinoma